NexMed Announces Patent Allowance for NexACT® in Canada
05 Maggio 2010 - 10:36PM
Business Wire
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced that the
Canadian Patent Office has issued a Notice of Allowance for
NexMed’s patent application entitled, “Crystalline Salts of Dodecyl
2-(N,N-Dimethylamino)-Propionate.” This patent, when issued, will
provide Canadian patent protection to May 2020, and is one in a
series of patents and pending applications that NexMed owns on the
NexACT technology and NexACT-based products under development.
Commenting on today’s news, Dr. Bassam Damaj, President and
Chief Executive Officer of NexMed, stated, “The Company has a
strong intellectual property position. In addition to the allowance
in Canada, we have corresponding coverage and protection for our
NexACT technology in the U.S. and other major markets. As we pursue
our growth goals, we are aggressively seeking to expand the patent
coverage for NexACT and to protect its potential for delivering new
classes of drugs and/or via new routes of administration such as
oral or subcutaneous delivery.”
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company
including but not limited to its ability to obtain and/or enforce
patent coverage in major markets.
Grafico Azioni Nexmed (MM) (NASDAQ:NEXM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Nexmed (MM) (NASDAQ:NEXM)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Nexmed (MM) (NASDAQ): 0 articoli recenti
Più NexMed, Inc. Articoli Notizie